Clinical trial
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic…
NCT00264849 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00264849 |
|---|---|
| Title | Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma |
| Official title | A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately… |
| Lead sponsor | Novartis, Industry |
| Collaborators | Genentech, Inc. Industry Tanox |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug, Other |
| Interventions | Omalizumab, Optimized asthma therapy |
| Enrollment | 406 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Dec 13, 2005 |
| Last update posted | Jun 29, 2018 |
| Countries | Belgium, Canada, Denmark, Germany, Greece, Hungary, Ireland, Israel, Italy, Norway, Poland, Portugal and 5 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: